论文部分内容阅读
目的探讨NET-1、EGFR在肺癌中的表达及临床意义。方法采用免疫组织化学SP法,检测120例肺癌及10例正常肺组织(对照组)中NET-1、EGFR的表达。结果 NET-1、EGFR在肺癌中的阳性表达率(85.00%、69.16%)明显高于癌旁肺组织(40.00%、10.00%)。NET-1、EGFR蛋白在肺癌中的表达差异与患者性别、年龄、病变部位无关(均P>0.05),但与肺癌组织的分化程度、临床分期、有无淋巴结转移相关(P<0.05)。结论 NET-1、EGFR具有促进肿瘤细胞转化、增殖、迁移的作用,可作为临床判定肺癌恶性程度的指标。
Objective To investigate the expression and clinical significance of NET-1 and EGFR in lung cancer. Methods Immunohistochemical SP method was used to detect the expression of NET-1 and EGFR in 120 cases of lung cancer and 10 cases of normal lung tissue (control group). Results The positive rates of NET-1 and EGFR in lung cancer (85.00%, 69.16%) were significantly higher than those in para-cancerous lung tissues (40.00%, 10.00%). There was no correlation between the expression of NET-1 and EGFR protein in lung cancer (P> 0.05), but not with gender, age and location (P> 0.05), but correlated with the degree of differentiation, clinical stage and lymph node metastasis (P <0.05). Conclusions NET-1 and EGFR can promote the transformation, proliferation and migration of tumor cells and can be used as an index to determine the malignant degree of lung cancer clinically.